Tiziana Life Sciences Ltd

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that members of its management and business development team will attend the 10th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting, known as MSToronto2026, being held October 21–23, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient has begun dosing in its Phase 2 trial of intranasal foralumab in early or mild Alzheimer's disease, with topline data expected in the first quarter of 2027.  The milestone completes enrollment and dosing initiation for all participants in the randomized, placebo-controlled study, the biotechnology company said.

BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with early/mild Alzheimer's disease (AD). Topline data are anticipated to be announced in Q1 2027.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare neurodegenerative disease with no approved disease-modifying therapies.  MSA is a rapidly progressive disorder that affects autonomic functions such as blood pressure and bladder control, as well as motor control, leading to severe disability and shortened life expectancy.